Multiple sclerosis symptom management

References

• Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med.338, 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Therapeutics. Cohen JA, Rudick RA (Eds). Informa Healthcare, London, UK 773–870 (2007).
   Google Scholar
• Stempein L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am. J. Phys. Med. Rehabil.79(6), 536–541 (2000).
   PubMed Web of Science ®Google Scholar
• Sylvester A, Sadiq S. Long term use of intrathecal baclofen infusion in ambulatory patients with spasticity. Neurology56, A26 (2001).
   Web of Science ®Google Scholar
• Bethoux F, Gogol D, Schwetz K, Kinkel RP. Use of a registry on intrathecal baclofen therapy in a large multiple sclerosis center: analysis of data on 82 patients and proposed changes. Poster 184. Arch. Phys. Med. Rehabil.82(9), 1329 (2001).
   Google Scholar
• Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J. Neurol. Neurosurg. Psychiatr.73(6), 705–709 (2002).
   PubMed Web of Science ®Google Scholar
• Patwardhan RV, Minagar A, Kelley RE, Nanda A. Neurosurgical treatment of multiple sclerosis. Neurol. Res.28(3), 320–325 (2006).
   PubMed Web of Science ®Google Scholar
• Smyth MD, Peacock WJ. The surgical treatment of spasticity. Muscle Nerve23(2), 153–163 (2000).
   PubMed Web of Science ®Google Scholar
• Bethoux F. Management of spasticity. In: Multiple Sclerosis Therapeutics. Cohen JA, Rudick RA (Eds). Informa Healthcare, London, UK 787–798 (2007).
   Google Scholar
• Tranchant C, Bhatia K, Marsden C. Movement disorders in multiple sclerosis. Mov. Disord.10, 418–423 (1995).
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cohen JA. Multiple sclerosis: the importance of early recognition and treatment. Cleve. Clin. J. Med.68, 157–171 (2001).
   PubMed Web of Science ®Google Scholar
• Geny C, Nguyen J, Pollin B et al. Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov. Disord.11, 489–494 (1996).
   PubMed Web of Science ®Google Scholar
• Benabid AL, Pollak P, Gao D et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment for movement disorders. J. Neurosurg.84, 203–214 (1996).
   PubMed Web of Science ®Google Scholar
• Herrera WG. Vestibular and other balance disorders in multiple sclerosis. Differential diagnosis of disequilibrium and topognostic localization. Neurol. Clin.8(2), 407–420 (1990).
   PubMed Web of Science ®Google Scholar
• Carter S, Sciarra D, Merritt HH. The course of multiple sclerosis as determined by autopsy proven cases. Res. Publ. Assoc. Res. Nerv. Ment. Dis.28, 471–511 (1950).
   PubMedGoogle Scholar
• Gass A, Steinke W, Schwartz A, Hennerici MG. High resolution magnetic resonance imaging in peripheral vestibular dysfunction in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.65(6), 945 (1998).
   PubMed Web of Science ®Google Scholar
• Thomke F, Hopf HC. Pontine lesions mimicking acute peripheral vestibulopathy. J. Neurol. Neurosurg. Psychiatr.66(3), 340–349 (1999).
   PubMed Web of Science ®Google Scholar
• Frohman EM, Kramer PD, Dewey RB, Kramer L, Frohman TC. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult. Scler.9(3), 250–255 (2003).
   PubMed Web of Science ®Google Scholar
• Frohman EM, Zhang H, Dewey RB et al. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology55(10), 1566–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Cattaneo D, De Nuzzo C, Fascia T et al. Risks of falls in subjects with multiple sclerosis. Arch. Phys. Med. Rehabil.83(6), 864–867 (2002).
   PubMed Web of Science ®Google Scholar
• Lord SE, Wade DT, Halligan PW. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin. Rehabil.12(6), 477–486 (1998).
   PubMed Web of Science ®Google Scholar
• Gallien P, Nicolas B, Robineau S et al. Physical training and multiple sclerosis. Ann. Readapt. Med. Phys.50(6), 373–376 (2007).
   PubMedGoogle Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology41, 685–691 (1991).
   PubMed Web of Science ®Google Scholar
• Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J. Consult. Clin. Psychol.53, 103–110 (1985).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Ellington L et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology41, 692–696 (1991).
   PubMed Web of Science ®Google Scholar
• Schultheis M, Garay E, DeLuca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology56, 1089–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Schultheis M, Garay E, Millis S, DeLuca J. Motor vehicle crashes and violations among drivers with multiple sclerosis. Arch. Phys. Med. Rehabil.83, 1175–1178 (2002).
   PubMed Web of Science ®Google Scholar
• Chipchase S, Lincoln N. Factors associated with carer strain in carers of people with multiple sclerosis. Disabil. Rehabil.23(17), 768–776 (2001).
   PubMed Web of Science ®Google Scholar
• Beatty W, Goodkin D, Hertsgaard D, Monson N. Clinical and demographic predictors of cognitive performance in multiple sclerosis. Do diagnostic type, disease duration, and disability matter? Arch. Neurol.47, 305–308 (1990).
   PubMed Web of Science ®Google Scholar
• Rovaris M, Filippi M, Falautano M et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology50, 1601–1608 (1998).
   PubMed Web of Science ®Google Scholar
• Berg D, Maurer M, Warmuth-Metz M, Rieckmann P, Becker G. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch. Neurol.57, 1289–1292 (2000).
   PubMedGoogle Scholar
• Zivadinov R, De Masi R, Nasuelli D et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting MS. Neuroradiology43, 272–278 (2001).
   PubMed Web of Science ®Google Scholar
• Beatty W, Goodkin D. Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination. Arch. Neurol.47(3), 297–301 (1990).
   PubMed Web of Science ®Google Scholar
• Swirsky-Sacchetti T, Field H, Mitchell D et al. The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J. Clin. Psychol.48(6), 779–786 (1992).
   PubMed Web of Science ®Google Scholar
• Aupperle R, Beatty W, Shelton Fde N, Gontkovsky S. Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult. Scler.8(5), 382–389 (2002).
   PubMed Web of Science ®Google Scholar
• Greene Y, Tariot P, Wishart H et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis abd associated cognitive impairments. J. Clin. Psychopharmacol.20, 350–356 (2000).
   PubMed Web of Science ®Google Scholar
• Krupp L, Christodoulou C, Melville P et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology63(9), 1579–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Remick RA, Allen J et al. Depression and multiple sclerosis. Neurology46, 628–632 (1996).
   PubMed Web of Science ®Google Scholar
• Edwards L, Constantinescu C. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis center. Mult. Scler.10, 575–581 (2004).
   PubMed Web of Science ®Google Scholar
• Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult. Scler.13(1), 67–72 (2007).
   PubMed Web of Science ®Google Scholar
• Wells K, Golding J, Burnam M. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am. J. Psychiatr.145, 976–981 (1988).
   PubMed Web of Science ®Google Scholar
• Sadovnick A, Eisen K, Ebers G, Paty D. Cause of death in patients attending multiple sclerosis clinics. Neurology41, 1193–1196 (1991).
   PubMed Web of Science ®Google Scholar
• Riudavets MA, Colegial C, Rubio A et al. Causes of unexpected death in patients with multiple sclerosis: a forensic study of 50 cases. Am. J. Forensic Med. Pathol.26(3), 244–249 (2005).
   PubMed Web of Science ®Google Scholar
• Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology59(5), 674–678 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor M, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J. Affect. Disord.88, 241–254 (2005).
   PubMed Web of Science ®Google Scholar
• Jefferson J, Pradko J, Muir K. Buproprion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther.27, 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Wernicke J, Gahimer J, Yalcin I et al. Safety and adverse event profile of duloxetine. Expert Opin. Drug Saf.4(6), 987–993 (2005).
   PubMedGoogle Scholar
• Foster H Jr. Bladder symptoms and multiple sclerosis. Mult. Scler. Quart. Rep.21, 5–8 (2002).
   Google Scholar
• Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol.81, 801–810 (1998).
   PubMedGoogle Scholar
• Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc.78, 687–695 (2003).
   PubMed Web of Science ®Google Scholar
• Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology65(1), 37–41 (2005).
   PubMed Web of Science ®Google Scholar
• de Seze M, Wiart L, de Seze MP et al. Reiterated intravesical instillation of capsaicin in neurogenic detrusor hyperreflexia: a 5-years experience of 100 instillations. Ann. Readapt. Med. Phys.44(8), 514–524 (2001).
   PubMedGoogle Scholar
• Smith CP, Somogyi GT, Chancellor MB. Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction. Curr. Urol. Rep.3(5), 382–387 (2002).
   PubMedGoogle Scholar
• Chia YW, Fowler CJ, Kamm MA et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J. Neurol.242(2), 105–108 (1995).
   PubMed Web of Science ®Google Scholar
• Zorzon M, Zivadinov R, Bosco A et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult. Scler.5(6), 418–427 (1999).
   PubMed Web of Science ®Google Scholar
• Hennessey A, Robertson N, Swingler R, Compston D. Urinary, faecal and sexual sysfunction in patients with multiple sclerosis. J. Neurol.246, 1027–1032 (1999).
   PubMed Web of Science ®Google Scholar
• DasGupta R, Fowler C. Bladder, bowel and sexual dysfunction in multiple sclerosis. Management strategies. Drugs63, 153–166 (2003).
   PubMed Web of Science ®Google Scholar
• Wiesel P, Norton C, Roy A et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.69, 240–243 (2000).
   PubMed Web of Science ®Google Scholar
• Miller AE, Bourdette DN, Cohen JA et al. Multiple Sclerosis. Clinical features of multiple sclerosis. Continuum5, 35–49 (1999).
   Google Scholar
• Hellstrom WJ, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology61(4 Suppl. 1), 8–14 (2003).
   PubMed Web of Science ®Google Scholar
• Skoumal R, Chen J, Kula K et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur. Urol.46(3), 362–369 (2004).
   PubMed Web of Science ®Google Scholar
• Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD. Efficacy of sildenafil in the treatment of female sexual dysfunction. J. Urol.171, 1189–1193 (2004).
   PubMed Web of Science ®Google Scholar
• Sipski M, Rosen R, Alexander C, Hamer R. Sildefanil effects on sexual and cardiovascular response in women with spinal cord injury. Urology55, 812–815 (2000).
   PubMed Web of Science ®Google Scholar
• Guidelines MSCfCP. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC, USA 1–46 (1998).
   Google Scholar
• Codella M, Rocca MA, Colombo B et al. A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. J. Neurol.249, 535–537 (2002).
   PubMed Web of Science ®Google Scholar
• Mainero C, Faroni J, Gasperini C et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J. Neurol.246, 454–458 (1999).
   PubMed Web of Science ®Google Scholar
• Fleming W, Pollack C. Sleep disorders in multiple sclerosis. Semin. Neurol.25, 64–68 (2005).
   PubMed Web of Science ®Google Scholar
• Tachibana N, Howard RS, Hirsch NP et al. Sleep problems in multiple sclerosis. Eur. Neurol.34, 320–323 (1994).
   PubMed Web of Science ®Google Scholar
• Krupp L, Coyle P, Doscher C et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology47(5), 1956–1961 (1995).
   Google Scholar
• Pucci E, Branas P, D’Amico R et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst. Rev.1, CD002818 (2007).
   Google Scholar
• Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatr.67(4), 554–566 (2006).
   PubMed Web of Science ®Google Scholar
• Provigil® (Modafinil), package insert. Cephalon, Inc. West Chester, PA, USA (2004).
   Google Scholar
• Challman TD, Lipsky JJ. Methyphenidate: its pharmacology and uses. Mayo Clin. Proc.75(7), 711–721 (2000).
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen JA, Cross A et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult. Scler.13(3), 357–368 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson A. Multiple sclerosis: symptomatic management. J. Neurol.243, 559–565 (1996).
   PubMed Web of Science ®Google Scholar
• Garg N, Weinstock-Guttman W. Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis. In: Multiple Sclerosis Therapeutics. Cohen JA, Rudick RA (Eds). Informa Healthcare, London, UK 845–862 (2007).
   Google Scholar
• McQuay H, Carroll D, Jadad A, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br. Med. J.311, 1047–1052 (1995).
   PubMed Web of Science ®Google Scholar
• Khan O. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology51, 611–614 (1998).
   PubMed Web of Science ®Google Scholar
• Moeen U, Zvartau-Hind M, Gilani A, Lisak R, Khan O. Topiramate relieves refractory trigeminal neuralgia in multiple sclerosis patients. Neurology54(Suppl. 3), A60 (2000) (Abstract).
   Google Scholar
• Besson J. The neurobiology of pain. Lancet353, 1610–1615 (1999).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol.60(11), 1524–1534 (2003).
   PubMed Web of Science ®Google Scholar